We also tested the potential of sPD-1 as an easily quantifiable marker of liver disease progression in the course of CHC, but the performance to discriminate mild (i.e., F0/1) from more advanced fibrosis (i.e., F2/F3) was relatively poor (AUC < 0.8). This evidence concerns the gene HOXD13 and liver disorder.